Our Semaglutide 1.5 mg/mL Sublingual Suspension is a meticulously crafted liquid formulation, specifically designed for sublingual administration. This advanced delivery system is delivered via oral syringe, which allows for precise dosing and ease of use. The formulation is particularly suitable for patients who require smaller doses or for those who may face challenges swallowing traditional solid dosage forms, such as tablets or capsules, including pediatric patients.

The Semaglutide Sublingual Suspension utilizes SubMagna™ SL HMW base, a cutting-edge vehicle that is tailored to enhance the delivery of a broad spectrum of drugs, especially those with high molecular weights. SubMagna SL HMW is an anhydrous, self-emulsifying base that transforms into an emulsion upon contact with saliva. This unique feature significantly improves the solubility and dispersibility of the active pharmaceutical ingredient (API), Semaglutide, under the tongue. The base's permeation-enhancing and mucoadhesive properties are pivotal in facilitating the absorption of the medication into the mucosal tissues, thereby extending contact time and potentially increasing bioavailability.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is primarily used in the treatment of type 2 diabetes mellitus. It works by stimulating insulin secretion and reducing glucagon secretion, which in turn helps to lower blood glucose levels. Additionally, Semaglutide has been shown to reduce cardiovascular events in patients with type 2 diabetes and to aid in weight management. The sublingual route of administration offered by our suspension bypasses the gastrointestinal tract, which can be particularly beneficial for patients who have conditions that affect the absorption of medications or those who experience gastrointestinal side effects.

The anhydrous nature of the SubMagna SL HMW base also contributes to the potential for extended beyond-use-dates (BUDs), offering an advantage in terms of the shelf-life of the suspension. This can be particularly beneficial for patients who do not require daily use of the medication or for those who prefer to have a supply on hand for convenience.

For patients and prescribers considering this innovative Semaglutide Sublingual Suspension, our team at Bayview Pharmacy is committed to providing comprehensive support and guidance. We understand the importance of personalized medication solutions and are here to answer any questions you may have about this formulation. Please do not hesitate to reach out to us for further information or assistance.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the management of type 2 diabetes mellitus to improve glycemic control, alongside diet and exercise. It functions by enhancing insulin secretion, suppressing glucagon secretion, and slowing gastric emptying. When considering drug interactions for semaglutide, it is important to note that the sublingual route of administration may alter the interaction profile compared to the more commonly used subcutaneous route.

One significant interaction to be aware of is with medications that affect gastrointestinal motility, as semaglutide slows gastric emptying. Concurrent use with other drugs that slow gastric emptying, such as opioids or anticholinergics, could enhance this effect and potentially lead to gastrointestinal adverse effects. Conversely, medications that increase gastric motility might decrease the effectiveness of semaglutide.

Patients taking insulin or insulin secretagogues, such as sulfonylureas, should be monitored closely for hypoglycemia when starting semaglutide. The insulin or sulfonylurea dose may need to be reduced to mitigate the risk of hypoglycemia. Additionally, semaglutide may enhance the effects of other antidiabetic agents, necessitating dose adjustments to avoid hypoglycemia.

It is also important to consider the potential for interactions with oral medications due to the sublingual route of administration. Since semaglutide can be absorbed directly into the bloodstream through the mucosal tissues, it may bypass hepatic first-pass metabolism, which could alter the pharmacokinetics of concurrently administered oral drugs that are subject to significant first-pass effect.

Furthermore, the use of SubMagna SL HMW base may influence the absorption of concomitant medications. The permeation-enhancing and mucoadhesive properties of the base could potentially alter the absorption of other sublingually administered drugs. Patients should be advised to separate the administration of semaglutide from other sublingual medications by a reasonable time interval to prevent any unintended interactions.

Patients should be counseled to avoid taking any medications that require an acidic gastric pH for absorption shortly after semaglutide, as the delayed gastric emptying could reduce the effectiveness of these drugs. Examples include certain antifungal agents like ketoconazole or itraconazole, and the protease inhibitor atazanavir.

Lastly, as with all medications, patients should be advised to inform their healthcare providers of all the medications they are taking, including over-the-counter drugs, herbal supplements, and vitamins, to ensure that potential interactions with semaglutide can be appropriately managed.

If you have any questions or require further information regarding the drug interactions associated with semaglutide 1.5 mg/mL sublingual suspension or its use in specific disease states, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is committed to providing comprehensive support to both patients and prescribers.

The semaglutide 1.5 mg/mL sublingual suspension is a cutting-edge formulation designed for the treatment of type 2 diabetes and, in some cases, chronic weight management. This liquid formulation is dispensed via oral syringe, allowing for precise and controlled administration. The medication is administered by emptying the contents of the oral syringe directly under the tongue, making it an ideal option for patients who may have difficulty swallowing tablets or capsules, or for those who require smaller doses.

How does it work? Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking the effects of the GLP-1 hormone, which is naturally produced in the body. GLP-1 plays a crucial role in regulating blood sugar levels by stimulating insulin secretion and lowering glucagon secretion when blood sugar levels are high. Additionally, it slows gastric emptying and reduces appetite, which can contribute to weight loss in patients with chronic weight management needs.

The innovative SubMagna™ SL HMW base used in this formulation is specifically designed to deliver a wide range of drugs, including those with high molecular weights like semaglutide. When administered sublingually, the anhydrous, self-emulsifying base of SubMagna™ SL HMW interacts with saliva to form an emulsion. This process enhances the solubility and dispersibility of the active pharmaceutical ingredient (API), semaglutide, in this case. The permeation-enhancing and mucoadhesive properties of the base promote the absorption of the molecule into the mucosal tissues under the tongue. This not only facilitates the entry of the drug into the systemic circulation but also prolongs the contact time between the drug and the absorption site, potentially leading to improved bioavailability.

By using the sublingual route, the semaglutide bypasses the gastrointestinal tract, which can degrade some medications or alter their absorption due to various factors such as pH, digestive enzymes, and food interactions. This direct entry into the bloodstream can lead to a more predictable pharmacokinetic profile and may reduce gastrointestinal side effects associated with GLP-1 receptor agonists.

The anhydrous nature of the SubMagna™ SL HMW base also contributes to the stability of the formulation, offering the potential for longer beyond-use-dates (BUDs), which is beneficial for both patients and prescribers by reducing medication waste and ensuring the availability of the medication when needed.

For patients and prescribers interested in this semaglutide sublingual suspension, it is important to understand that this formulation is specifically designed to improve the management of type 2 diabetes and may assist in weight management for certain patients.

If you have any questions or require further information about the semaglutide 1.5 mg/mL sublingual suspension, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is here to provide the support and guidance you need to make informed decisions about your health care options.

While the primary indication for Semaglutide 1.5 mg/mL Sublingual Suspension is the management of type 2 diabetes, the unique properties of the SubMagna™ SL HMW base may allow for its use in other therapeutic areas. The sublingual route of administration bypasses the gastrointestinal tract, which can be particularly beneficial for patients with gastrointestinal disorders that affect the absorption of oral medications. Additionally, this route can be advantageous for drugs that undergo significant first-pass metabolism, potentially allowing for a reduction in dose and associated side effects.

Given the permeation-enhancing and mucoadhesive characteristics of the SubMagna™ SL HMW base, this formulation could be explored for use with other high molecular weight drugs that require enhanced absorption into the systemic circulation. For instance, certain peptides and proteins that are typically administered via injection might be candidates for sublingual delivery using this system, potentially improving patient compliance and comfort. Moreover, the anhydrous nature of the base may extend the beyond-use date of the formulation, which is particularly useful for drugs that are sensitive to degradation in aqueous environments.

It is also conceivable that the sublingual suspension could be used in the management of acute conditions where rapid onset of action is desired, as the sublingual route can offer quicker absorption compared to traditional oral administration. This could be relevant in the treatment of pain, nausea, or anxiety, where prompt relief of symptoms is crucial. However, it is important to note that the use of Semaglutide in conditions other than type 2 diabetes has not been established and would require further investigation and approval by regulatory authorities.

Patients and prescribers interested in exploring the potential of Semaglutide 1.5 mg/mL Sublingual Suspension for off-label uses should proceed with caution and consider the current evidence and guidelines. It is essential to consult with a healthcare professional before using this medication for any unapproved indication. For more detailed information or to discuss specific patient needs, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is equipped to provide guidance and support for your unique medication requirements.